Year ended | Year ended | ||
31 December 2024 | 31 December 2023 | ||
Notes | £m | £m | |
Continuing operations | |||
Revenue | 5 | ||
Operating expenses | 6 | ( | ( |
Losses on trade receivables | 6 | ( | ( |
Other income | |||
Operating profit | |||
Net finance costs | 10 | ( | ( |
Profit before tax | |||
Income tax expense | 11 | ( | ( |
Profit for the year | |||
Attributable to: | |||
Equity holders of the parent | |||
Non-controlling interest | |||
Earnings per share attributable to equity holders: | |||
Basic earnings per share (pence) | 12 | ||
Diluted earnings per share (pence) | 12 | ||
Reconciliation to Adjusted EBITDA: | |||
Operating profit | |||
Depreciation | |||
Amortisation of software | |||
Adjusting items | 7 | ||
Adjusted EBITDA |
Year ended | Year ended | ||
31 December 2024 | 31 December 2023 | ||
Notes | £m | £m | |
Profit for the year | |||
Other comprehensive income | |||
Items that will be classified subsequently to profit or loss | |||
when specific conditions are met: | |||
Cash flow hedge – effective portion of changes in fair value | 16 | ||
Cash flow hedge – reclassification to profit or loss | 16 | ||
Net exchange gain/(loss) on translation of foreign entities | 24 | ( | |
Other comprehensive income, net of tax | |||
Total comprehensive income for the year | |||
Attributable to: | |||
Equity holders of the parent | |||
Non-controlling interest |
31 December 2024 | 31 December 2023 | ||
Notes | £m | £m | |
Non-current assets | |||
Property, plant and equipment | 14 | ||
Goodwill | 13 | ||
Other intangible assets | 13 | ||
Investment in associate | 28 | ||
Deferred tax assets | 18 | ||
Current assets | |||
Trade and other receivables | 17 | ||
Current tax receivable | |||
Short-term derivative assets | 16 | ||
Cash and cash equivalents | |||
Total assets | |||
Current liabilities | |||
Trade and other payables | 19 | ( | ( |
Deferred revenue | 5 | ( | ( |
Short-term lease liabilities | 15 | ( | ( |
Current tax payable | ( | ( | |
Short-term derivative liabilities | 16 | ( | ( |
Short-term provisions | 23 | ( | ( |
( | ( | ||
Net current liabilities | ( | ( | |
Non-current liabilities | |||
Long-term trade and other payables | 19 | ( | |
Deferred revenue | 5 | ( | |
Long-term provisions | 23 | ( | ( |
Deferred tax liabilities | 18 | ( | |
Long-term derivative liabilities | 16 | ( | |
Long-term lease liabilities | 15 | ( | ( |
Long-term borrowings | 20 | ( | ( |
( | ( | ||
Total liabilities | ( | ( | |
Net assets | |||
Equity | |||
Share capital | 24 | ||
Treasury reserve | 24 | ( | ( |
Other reserve | 24 | ( | ( |
Foreign currency translation reserve | 24 | ( | ( |
Retained profit | |||
Equity attributable to equity holders of the parent | |||
Non-controlling interest | 24 | ||
Total equity |
Equity | ||||||||||
Foreign | attributable | |||||||||
Cash flow | currency | to equity | Non- | |||||||
Share | Treasury | Other | hedge | translation | Retained | holders of | controlling | Total | ||
capital | reserve | reserve | reserve | reserve | profit | the parent | interest | equity | ||
Notes | £m | £m | £m | £m | £m | £m | £m | £m | £m | |
Balance at 1 January 2023 | ( | ( | ( | ( | ||||||
Profit for the year | ||||||||||
Other comprehensive income: | ||||||||||
Cash flow hedge – reclassification to profit or loss upon loan repayment | 16 | |||||||||
Cash flow hedge – effective | ||||||||||
portion of changes in fair value | 16 | |||||||||
Cash flow hedge – reclassification to profit or loss upon discontinuation of hedge accounting | 16 | |||||||||
Net exchange loss on translation | ||||||||||
of foreign entities | 24 | ( | ( | ( | ||||||
Total comprehensive income | ||||||||||
for the year | ( | |||||||||
Transactions with owners: | ||||||||||
Share buyback | 24 | ( | ( | ( | ||||||
Dividends | 24 | ( | ( | ( | ||||||
Vesting of share options | 25 | ( | ||||||||
Share-based payments charge | 25 | |||||||||
Tax on share-based payments | 11 | |||||||||
Balance at 31 December 2023 | ( | ( | ( | |||||||
Profit for the year | ||||||||||
Other comprehensive income: | ||||||||||
Net exchange (loss)/gain on translation | ||||||||||
of foreign entities | 24 | ( | ( | |||||||
Total comprehensive income | ||||||||||
for the year | ( | |||||||||
Transactions with owners: | ||||||||||
Share buyback | 24 | ( | ( | ( | ||||||
Dividends | 24 | ( | ( | ( | ||||||
Vesting of share options | 25 | ( | ||||||||
Gain from sale of 40% of Healthcare | ||||||||||
business, net of transaction | ||||||||||
costs incurred | 24 | ( | ||||||||
Equity issued to holders of non-controlling interest | 24 | |||||||||
Share buyback and cancellation | ||||||||||
scheme | 24 | ( | ( | ( | ||||||
Share-based payments charge | 25 | |||||||||
Tax on share-based payments | 11 | |||||||||
Balance at 31 December 2024 | ( | ( | ( |
Year ended | Year ended | ||
31 December 2024 | 31 December 2023 | ||
Notes | £m | £m | |
Cash flows from operating activities | |||
Profit for the year | |||
Adjustments for: | |||
Depreciation | 14 | ||
Amortisation | 13 | ||
Other income | ( | ( | |
Net finance costs | 10 | ||
Taxation recognised in profit or loss | 11 | ||
Share-based payments charge | 25 | ||
Increase in trade and other receivables | 22 | ( | ( |
Increase/(decrease) in trade and other payables | 22 | ( | |
Revaluation of short- and long-term derivatives | 16 | ( | |
Increase in provisions | 23 | ||
Cash generated from operations | |||
Interest paid | ( | ( | |
Income taxes paid | ( | ( | |
Contingent consideration paid | 27 | ( | ( |
Total cash flows from operating activities | |||
Cash flows from investing activities | |||
Acquisitions | 27 | ( | |
Purchase of property, plant and equipment | 14 | ( | ( |
Purchase of intangible assets | 13 | ( | ( |
Total cash flows used in investing activities | ( | ( | |
Cash flows from financing activities | |||
Receipt of loan from related party | 24 | ||
Settlement of borrowings in relation to acquisitions | 27 | ( | |
Proceeds from sale of 40% of Healthcare business | |||
to non-controlling interest | 24 | ||
Transaction costs relating to sale of 40% of Healthcare business to non-controlling interest | 24 | ( | |
Repayment of borrowings | 20 | ( | ( |
Proceeds from borrowings | 20 | ||
Loan refinancing fee | 20 | ( | |
Acquisition of own shares | 24 | ( | ( |
Acquisition of own shares for cancellation | 24 | ( | |
Principal elements of lease payments | 20 | ( | ( |
Dividends paid | 24 | ( | ( |
Total cash flows from/(used in) financing activities | ( | ||
Net increase/(decrease) in cash and cash equivalents | ( | ||
Cash and cash equivalents at beginning of year | |||
Effects of currency translation on cash and cash equivalents | ( | ||
Cash and cash equivalents at end of year |
Share-based payments and associated costs | Share-based payment expenses are excluded from Adjusted EBITDA as they |
are a non-cash charge and the awards are equity-settled. | |
Restructuring and refinancing costs | The Group excludes these costs from Adjusted EBITDA where the nature of the |
item, or its size, is not related to the operational performance of the Group and | |
allows for comparability of underlying results. | |
Acquisition and integration costs (including | The Group excludes these costs from Adjusted EBITDA where the nature of the |
contingent consideration) | item, or its size, is not related to the operational performance of the Group and |
allows for comparability of underlying results. | |
Amortisation and impairment of acquired | The amortisation charge for those intangible assets recognised on business |
intangible assets | combinations is excluded from Adjusted EBITDA since they are non-cash |
charges arising from historical investment activities. Any impairment charges | |
recognised in relation to these intangible assets are also excluded from | |
Adjusted EBITDA. This is a common adjustment made by acquisitive | |
information service businesses and is therefore c onsistent with peers. Revenues | |
associated with acquisitions, in the year of acquisition, are excluded from the | |
calculation of underlying revenue. | |
Revaluation of short- and long-term derivatives | Gains and losses are recognised within Adjusted EBITDA when they are realised |
Unrealised operating foreign exchange | in cash terms and therefore we exclude non-cash movements arising from |
gain/loss | fluctuations in exchange rates which better aligns Adjusted EBITDA with the |
cash performance of the business. | |
Revaluation of interest rate swap | Gains and losses on the revaluation of the interest rate swap are excluded from |
Adjusted profit before tax which better aligns with the cash per formance of the | |
business. |
DA&I: | DA&I: | |||
Healthcare | Non-Healthcare | Corporate | Total | |
£m | £m | £m | £m | |
Revenue | 109.4 | 176.1 | – | 285.5 |
Operating costs | (48.5) | (117.9) | (2.3) | (168.7) |
Adjusted EBITDA | 60.9 | 58.2 | (2.3) | 116.8 |
Share-based payments charge | (24.1) | |||
Restructuring and refinancing costs | (5.3) | |||
Acquisition and integration costs | (4.0) | |||
Costs relating to share-based payment schemes | (0.3) | |||
Revaluation loss on short- and long-term derivatives | (1.7) | |||
Unrealised operating foreign exchange gain | 0.3 | |||
Amortisation of acquired intangibles | (8.9) | |||
Amortisation (excluding amortisation of acquired | ||||
intangible assets) | (1.9) | |||
Depreciation | (5.8) | |||
Finance costs | (10.2) | |||
Profit before tax | 54.9 |
DA&I: | DA&I: | |||
Healthcare | Non-Healthcare | Corporate | Total | |
£m | £m | £m | £m | |
Revenue | 102.6 | 170.5 | – | 273.1 |
Operating costs | (45.7) | (114.6) | (2.0) | (162.3) |
Adjusted EBITDA | 56.9 | 55.9 | (2.0) | 110.8 |
Share-based payments charge | (19.4) | |||
Restructuring and refinancing costs | (1.7) | |||
Acquisition and integration costs | (1.3) | |||
Costs relating to share-based payment schemes | (0.2) | |||
Revaluation gain on short- and long-term derivatives | 0.8 | |||
Unrealised operating foreign exchange gain | 1.5 | |||
Amortisation of acquired intangibles | (9.0) | |||
Amortisation (excluding amortisation of acquired | ||||
intangible assets) | (1.6) | |||
Depreciation | (6.2) | |||
Finance costs | (32.2) | |||
Profit before tax | 41.5 |
Asia | Rest of | ||||||
UK | Europe | Americas 1 | Pacific | MENA 2 | World | Total | |
£m | £m | £m | £m | £m | £m | £m | |
Revenue from external customers | 44.3 | 78.2 | 104.0 | 27.7 | 22.2 | 9.1 | 285.5 |
Asia | Rest of | ||||||
UK | Europe | Americas 1 | Pacific | MENA 2 | World | Total | |
£m | £m | £m | £m | £m | £m | £m | |
Revenue from external customers | 43.4 | 73.9 | 99.1 | 27.9 | 20.4 | 8.4 | 273.1 |
Deferred Revenue recognised within | ||||
Revenue recognised in the | the Consolidated Statement of | |||
Consolidated Income Statement | Financial Position | |||
Year ended | Year ended | As at | As at | |
31 December 2024 | 31 December 2023 | 31 December 2024 | 31 December 2023 | |
Restated* | ||||
£m | £m | £m | £m | |
Services transferred: | ||||
Over a period of time | 215.2 | 210.7 | 101.6 | 89.5 |
At a point in time | 70.3 | 62.4 | 13.0 | 15.1 |
Total | 285.5 | 273.1 | 114.6 | 104.6 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Cost of sales | 136.6 | 132.0 |
Administrative costs | 83.4 | 65.7 |
220.0 | 197.7 | |
Losses on trade receivables | 1.0 | 2.3 |
Total operating expenses | 221.0 | 200.0 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Depreciation of property, plant and equipment | 5.8 | 6.2 |
Amortisation of intangible assets | 10.8 | 10.6 |
Gain (including realised and unrealised) on foreign exchange | (1.0) | (1.0) |
Auditor’s remuneration | 1.8 | 1.3 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Audit of the Company’s and the consolidated financial statements | 0.8 | 0.6 |
Audit of the subsidiary companies’ financial statements | 0.9 | 0.6 |
All other services (including half year review) | 0.1 | 0.1 |
Total auditor’s remuneration | 1.8 | 1.3 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Share-based payment charge | 24.1 | 19.4 |
Amortisation of acquired intangibles | 8.9 | 9.0 |
Restructuring and refinancing costs | 5.3 | 1.7 |
Acquisition and integration costs | 4.0 | 1.3 |
Costs relating to share-based payments scheme | 0.3 | 0.2 |
Revaluation loss/(gain) on short and long-term derivatives | 1.7 | (0.8) |
Unrealised operating foreign exchange gain | (0.3) | (1.5) |
Total adjusting items | 44.0 | 29.3 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Wages and salaries | 121.9 | 116.5 |
Social security costs | 9.8 | 8.8 |
Pension costs | 1.8 | 1.8 |
Share-based payments charge (note 25) | 24.1 | 19.4 |
157.6 | 146.5 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
No. | No. | |
Researchers and analysts | 2,783 | 2,859 |
Sales and admin | 774 | 701 |
3,557 | 3,560 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Short-term employee benefits | 3.7 | 5.1 |
Post-employment benefits | 0.1 | 0.1 |
Share-based payments | 8.7 | 11.8 |
12.5 | 17.0 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Loan interest cost | 13.6 | 28.6 |
Lease interest cost | 1.1 | 1.1 |
Revaluation of interest rate swap | (2.8) | 2.8 |
Other interest cost | – | 0.1 |
Other interest income | (1.7) | (0.4) |
10.2 | 32.2 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Income statement | ||
Current income tax: | ||
Current income tax | (43.3) | (17.2) |
Adjustments in respect of prior years | 0.3 | 1.3 |
(43.0) | (15.9) | |
Deferred income tax: | ||
Relating to origination and reversal of temporary differences | 25.1 | 4.4 |
Effect of change in tax rates | (0.1) | 0.4 |
Adjustments in respect of deferred tax of previous years | (0.8) | 0.1 |
Movement in unrecognised deferred tax | 0.4 | 0.3 |
24.6 | 5.2 | |
Total income tax expense in income statement | (18.4) | (10.7) |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Recognised in statement of changes in equity | ||
Corporation tax income on share options exercised | 0.4 | 1.7 |
Deferred tax expense on share-based payments | – | (0.9) |
Total tax income recognised directly in equity | 0.4 | 0.8 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Profit before tax | 54.9 | 41.5 |
Tax at the UK corporation tax rate of 25.0% (2023: 23.5%) | (13.7) | (9.8) |
Effects of: | ||
Non-taxable income for tax purposes | 0.1 | 0.1 |
Non-deductible expenses for tax purposes | (1.9) | (1.3) |
Fixed asset disposals | (0.1) | – |
Movement in share-based payments | (0.5) | (0.1) |
Effect of tax rates in overseas jurisdictions | 0.7 | 0.2 |
Overseas tax | (2.8) | (1.9) |
Effect of change in tax rates | (0.1) | 0.4 |
Adjustments in respect of current income tax of previous years | (0.5) | 1.4 |
Movement in unrecognised deferred tax | 0.4 | 0.3 |
(18.4) | (10.7) |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
Earnings per share attributable to equity holders from continuing operations: | ||
Basic | ||
Profit for the period attributable to equity shareholders (£m) | 36.5 | 30.8 |
Less: non-controlling interest (£m) | (6.9) | – |
Profit for the period attributable to ordinary shareholders of the parent company (£m) | 29.6 | 30.8 |
Weighted average number of shares (no’ m) | 789.1 | 807.1 |
Basic earnings per share (pence) | 3.8 | 3.8 |
Diluted | ||
Profit for the period attributable to equity shareholders (£m) | 36.5 | 30.8 |
Less: non-controlling interest (£m) | (6.9) | – |
Profit for the period attributable to ordinary shareholders of the parent company (£m) | 29.6 | 30.8 |
Weighted average number of shares (no’ m) | 799.4 | 818.2 |
Diluted earnings per share (pence) | 3.7 | 3.8 |
Year ended | Year ended | |
31 December 2024 | 31 December 2023 | |
No’ m | No’ m | |
Basic weighted average number of shares, net of shares held in treasur y reserve | 789.1 | 807.1 |
Dilutive share options in issue – scheme 1 | 1.2 | 4.5 |
Dilutive share options in issue – scheme 2 | 6.5 | 6.6 |
Dilutive share options in issue – scheme 4 | 2.6 | – |
Diluted weighted average number of shares | 799.4 | 818.2 |
Potentially dilutive shares | 2026 | 2027 | Total |
Schedule | No. | No. | No. |
Scheme 2 | 6,250,000 | 6,250,000 | 12,500,000 |
Scheme 4 | 5,023,015 | 17,580,553 | 22,603,568 |
Total | 11,273,015 | 23,830,553 | 35,103,568 |
IP rights | |||||||
Customer | and | ||||||
AUC* | Software | relationships | Brands | database | Goodwill | Total | |
£m | £m | £m | £m | £m | £m | £m | |
Cost | |||||||
As at 1 January 2023 | – | 15.4 | 65.3 | 26.2 | 77.9 | 322.0 | 506.8 |
Additions: Internally developed | 0.2 | 2.3 | – | – | – | – | 2.5 |
Additions: Separately acquired | – | 0.7 | – | 0.1 | – | – | 0.8 |
As at 31 December 2023 | 0.2 | 18.4 | 65.3 | 26.3 | 77.9 | 322.0 | 510.1 |
Additions: Business combinations | – | 1.7 | 26.3 | 9.4 | 8.9 | 46.1 | 92.4 |
Additions: Internally developed | 4.9 | – | – | – | – | – | 4.9 |
Additions: Separately acquired | – | 0.4 | – | 0.2 | – | – | 0.6 |
Transfer AUC to software | (0.5) | 0.5 | – | – | – | – | – |
Foreign currency retranslation | – | 0.1 | – | – | – | – | 0.1 |
Disposals | – | (0.1) | – | – | – | – | (0.1) |
As at 31 December 2024 | 4.6 | 21.0 | 91.6 | 35.9 | 86.8 | 368.1 | 608.0 |
Amortisation | |||||||
As at 1 January 2023 | – | (12.9) | (37.8) | (12.2) | (52.9) | (10.9) | (126.7) |
Charge for the year | – | (1.6) | (4.7) | (1.2) | (3.1) | – | (10.6) |
As at 31 December 2023 | – | (14.5) | (42.5) | (13.4) | (56.0) | (10.9) | (137.3) |
Additions: Business combinations | – | (1.1) | – | – | – | – | (1.1) |
Charge for the year | – | (1.9) | (4.4) | (1.3) | (3.2) | – | (10.8) |
Disposals | – | 0.1 | – | – | – | – | 0.1 |
As at 31 December 2024 | – | (17.4) | (46.9) | (14.7) | (59.2) | (10.9) | (149.1) |
Net book value | |||||||
As at 31 December 2024 | 4.6 | 3.6 | 44.7 | 21.2 | 27.6 | 357.2 | 458.9 |
As at 31 December 2023 | 0.2 | 3.9 | 22.8 | 12.9 | 21.9 | 311.1 | 372.8 |
Customer relationships | Brands | IP rights and database | ||||
Carrying | Remaining | Carrying | Remaining | Carrying | Remaining | |
value | amortisation | value | amortisation | value | amortisation | |
£m | period | £m | period | £m | period | |
Infinata | 0.3 | 1 year | – | – | – | – |
AROQ | 0.4 | 4 years | – | – | – | – |
Research Views | 2.7 | 1-6 years | – | – | – | – |
GlobalData | – | – | 2.5 | 6 years | – | – |
Verdict | – | – | 0.7 | 3 years | – | – |
Progressive Content | 0.2 | 3 years | – | – | 0.1 | 1 year |
Life Sciences | 2.9 | 7 years | – | – | 7.2 | 8 years |
LMC | 5.1 | 3-9 years | – | – | 10.5 | 7 years |
MBI | 4.0 | 3-8 years | 8.2 | 17 years | 0.2 | 3 years |
TS Lombard | 3.1 | 8-11 years | 0.5 | 18 years | 0.8 | 3 years |
BTMI | 1.8 | 4 years | 1.8 | 10 years | 0.4 | 5 years |
LinkUp | 9.5 | 12 years | 0.7 | 10 years | 3.1 | 15 years |
Celent | 4.6 | 6 years | 1.2 | 10 years | 5.3 | 10 years |
Deallus | 10.1 | 19 years | 5.6 | 15 years | – | – |
Total carrying value | 44.7 | 21.2 | 27.6 |
Increase in revenue | Increase in costs | Pre-tax | Terminal growth | |||||
(for years 1 to 5) | (for years 1 to 5) | discount rate | rate | |||||
2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |
DA&I: Healthcare | 10.1% | – | 2.0% | – | 13.1% | – | 2.0% | – |
DA&I: Non-Healthcare | 5.3% | – | 2.0% | – | 12.9% | – | 2.0% | – |
MBI | 3.8% | 3.0% | 2.0% | 2.0% | 12.8% | 13.6% | 2.0% | 2.0% |
Increase in revenue | Increase in costs | Pre-tax | Terminal growth | |
(for years 1 to 5) | (for years 1 to 5) | discount rate | rate | |
2023 | 2023 | 2023 | 2023 | |
DA&I | 7.7% | 2.0% | 13.6% | 2.0% |
Revenue growth | Discount rate | |
Cash-generating unit | falls by* | rises by* |
DA&I: Healthcare | (24.7%) | 44.9% |
DA&I: Non-Healthcare | (8.6%) | 13.6% |
MBI | (2.8%) | 4.1% |
Fixtures, fittings & | Leasehold | |||
Buildings | equipment | improvements | Total | |
£m | £m | £m | £m | |
Cost | ||||
As at 1 January 2023 | 44.2 | 8.7 | 2.1 | 55.0 |
Additions: Separately acquired | 1.5 | 0.6 | 0.3 | 2.4 |
Foreign currency retranslation | (0.7) | (0.2) | – | (0.9) |
Disposals | (1.5) | (0.4) | – | (1.9) |
As at 31 December 2023 | 43.5 | 8.7 | 2.4 | 54.6 |
Additions: Business combinations | 1.4 | 0.8 | 0.2 | 2.4 |
Additions: Separately acquired | 4.2 | 1.6 | 0.1 | 5.9 |
Foreign currency retranslation | (0.1) | (0.1) | – | (0.2) |
Disposals | (6.4) | (0.2) | – | (6.6) |
As at 31 December 2024 | 42.6 | 10.8 | 2.7 | 56.1 |
Depreciation | ||||
As at 1 January 2023 | (16.2) | (7.1) | (0.7) | (24.0) |
Charge for the year | (5.1) | (0.9) | (0.2) | (6.2) |
Foreign currency retranslation | 0.5 | 0.2 | – | 0.7 |
Disposals | 1.1 | 0.4 | – | 1.5 |
As at 31 December 2023 | (19.7) | (7.4) | (0.9) | (28.0) |
Additions: Business combinations | – | (0.5) | – | (0.5) |
Charge for the year | (4.6) | (0.9) | (0.3) | (5.8) |
Foreign currency retranslation | – | 0.1 | – | 0.1 |
Disposals | 6.0 | 0.2 | – | 6.2 |
As at 31 December 2024 | (18.3) | (8.5) | (1.2) | (28.0) |
Net book value | ||||
As at 31 December 2024 | 24.3 | 2.3 | 1.5 | 28.1 |
As at 31 December 2023 | 23.8 | 1.3 | 1.5 | 26.6 |
Buildings | |
£m | |
Cost | |
As at 1 January 2023 | 44.2 |
Additions: Separately acquired | 1.5 |
Foreign currency retranslation | (0.7) |
Disposals | (1.5) |
As at 31 December 2023 | 43.5 |
Additions: Business combinations | 1.4 |
Additions: Separately acquired | 4.2 |
Foreign currency retranslation | (0.1) |
Disposals | (6.4) |
As at 31 December 2024 | 42.6 |
Depreciation | |
As at 1 January 2023 | (16.2) |
Charge for the year | (5.1) |
Foreign currency retranslation | 0.5 |
Disposals | 1.1 |
As at 31 December 2023 | (19.7) |
Charge for the year | (4.6) |
Disposals | 6.0 |
As at 31 December 2024 | (18.3) |
Net book value | |
As at 31 December 2024 | 24.3 |
As at 31 December 2023 | 23.8 |
31 December | 31 December | |
2024 | 2023 | |
£m | £m | |
Current lease liabilities | 4.0 | 4.3 |
Non-current lease liabilities | 22.1 | 21.4 |
26.1 | 25.7 |
No. of | |||||
No. of right-of- | Range of | Average | No. of leases | leases with | |
use assets | remaining | remaining | with extension | termination | |
leased | term | lease term | options | options | |
Office buildings | 23 | 0-9 years | 3 years | 0 | 1 |
Within one | One to | After | ||
year | five years | five years | Total | |
As at 31 December 2024 | £m | £m | £m | £m |
Lease payments | 5.1 | 15.5 | 10.0 | 30.6 |
Finance charges | (1.1) | (2.7) | (0.7) | (4.5) |
Net present values | 4.0 | 12.8 | 9.3 | 26.1 |
Within one | One to | After | ||
year | five years | five years | Total | |
As at 31 December 2023 | £m | £m | £m | £m |
Lease payments | 5.2 | 12.7 | 12.2 | 30.1 |
Finance charges | (0.9) | (2.4) | (1.1) | (4.4) |
Net present values | 4.3 | 10.3 | 11.1 | 25.7 |
31 December 2024 | 31 December 2023 | |||
Assets | Liabilities | Assets | Liabilities | |
£m | £m | £m | £m | |
Held-for-trading*: | ||||
– Interest rate swaps | – | – | – | (2.8) |
– Forward foreign currency contracts | – | (1.3) | 0.5 | (0.1) |
Total | – | (1.3) | 0.5 | (2.9) |
Current: | – | (1.3) | 0.5 | (0.1) |
Non-current: | – | – | – | (2.8) |
Change in fair value | ||||
of the hedging | ||||
instrument used as the | ||||
Financial | basis for recognising | |||
statement | hedge ineffectiveness | Nominal amount of | ||
Hedging instrument | Carrying value | line item | for the period | hedging instrument |
Interest rate swap | 2024: £nil | 2024: N/A | 2024: N/A | 2024: £nil |
2023: £2.8m liability | 2023: Long-term | 2023: N/A – hedge | 2023: £265.0m | |
derivative liabilities | 100% effective |
31 December 2024 | 31 December 2023 | |
Cash Flow Hedge Reserve – Interest Rate Risk | £m | £m |
Cash Flow Hedge Reserve balance brought forward | – | (3.9) |
Change in fair value of hedging instrument upon loan repayment – | ||
reclassification from OCI to profit or loss | – | 0.4 |
Change in fair value of hedging instrument recognised in OCI | – | 0.7 |
Change in fair value of hedging instrument – reversal of cumulative | ||
reserve held in OCI upon discontinuation of hedge accounting | – | 2.8 |
Cash Flow Hedge Reserve balance carried forward | – | – |
Euro | US Dollar | |
€m | $m | |
Expiring in the year ending: | ||
31 December 2025 | 2.7 | 15.2 |
US Dollar | |
$m | |
Expiring in the year ending: | |
31 December 2025 | 10.0 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Trade receivables | 74.0 | 54.8 |
Prepayments | 11.0 | 11.0 |
Other receivables | 2.7 | 0.8 |
Accrued income | 2.2 | 2.6 |
89.9 | 69.2 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Not overdue | 44.7 | 28.6 |
Overdue by up to one month | 13.2 | 14.3 |
More than one month but not more than three months overdue | 10.4 | 8.2 |
More than three months but not more than one year overdue | 5.7 | 3.7 |
74.0 | 54.8 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Not overdue | – | – |
Overdue by up to one month | – | – |
More than one month but not more than three months overdue | 0.4 | 0.4 |
More than three months overdue | 3.6 | 3.9 |
4.0 | 4.3 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Pounds Sterling | 24.8 | 21.8 |
US Dollar | 41.9 | 30.0 |
Euro | 7.7 | 4.6 |
Australian Dollar | 0.6 | 0.5 |
Other | 3.0 | 2.2 |
78.0 | 59.1 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Opening expected credit loss allowance | 4.3 | 3.4 |
Increase in loss allowance | 1.0 | 2.3 |
Receivables written off during the year as uncollectable | (1.3) | (1.4) |
Closing expected credit loss allowance | 4.0 | 4.3 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Opening credit note provision | – | 0.1 |
Credit notes raised during the year | – | (0.1) |
Closing credit note provision | – | – |
31 December 2024 | ||||||||
Days | 0-30 | 31-60 | 61-90 | 91-120 | 121-150 | 151-365 | 365+ | Total |
Net exposure (£m) | 13.6 | 3.3 | 1.4 | 1.7 | 1.3 | 3.1 | 1.0 | 25.4 |
ECL rate | 2.2% | 4.7% | 7.7% | 18.0% | 23.7% | 58.2% | 100.0% | |
Provision (£m) | 0.3 | 0.2 | 0.1 | 0.3 | 0.3 | 1.8 | 1.0 | 4.0 |
31 December 2023 | ||||||||
Days | 0-30 | 31-60 | 61-90 | 91-120 | 121-150 | 151-365 | 365+ | Total |
Net exposure (£m) | 9.5 | 2.2 | 1.4 | 1.0 | 1.5 | 3.3 | 0.8 | 19.7 |
ECL rate | 2.5% | 3.9% | 12.2% | 15.4% | 36.1% | 70.7% | 100.0% | |
Provision (£m) | 0.2 | 0.1 | 0.2 | 0.2 | 0.5 | 2.3 | 0.8 | 4.3 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Balance brought forward | 2.5 | (1.8) |
Tax income during the period recognised in profit or loss | 24.6 | 5.2 |
Tax expense during the period recognised directly in equity | – | (0.9) |
Deferred taxes acquired in business combinations | (5.1) | – |
Balance carried forward | 22.0 | 2.5 |
The provision for deferred taxation consists of the tax effect of temporary differences in respect of: | ||
Accelerated depreciation for tax purposes | (0.4) | (1.0) |
Losses available for offsetting against future taxable income | 4.8 | 1.6 |
Share-based payments | 9.7 | 8.2 |
Business combinations – revaluations of intangible assets to fair value | ||
(deferred tax asset) | 24.2 | – |
Business combinations – revaluations of intangible assets to fair value | ||
(deferred tax liability) | (22.4) | (11.7) |
Restricted interest carried forward | 3.4 | 4.5 |
Other temporary differences | 2.7 | 0.9 |
Balance carried forward | 22.0 | 2.5 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Deferred tax asset | 22.0 | 3.4 |
Deferred tax liability | – | (0.9) |
Net position | 22.0 | 2.5 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Trade payables | 15.1 | 10.8 |
Amounts due to related parties | 1.0 | – |
Other taxation and social security | 4.6 | 2.0 |
Accruals | 22.5 | 19.6 |
Current liabilities | 43.2 | 32.4 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Accruals | 2.7 | – |
Non-current liabilities | 2.7 | – |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Short-term lease liabilities | 4.0 | 4.3 |
Current liabilities | 4.0 | 4.3 |
Long-term lease liabilities | 22.1 | 21.4 |
Long-term borrowings | 40.4 | 263.7 |
Non-current liabilities | 62.5 | 285.1 |
Short-term | Long-term | ||||
Short-term | Long-term | lease | lease | ||
borrowings | borrowings | liabilities 1 | liabilities 1 | Total | |
£m | £m | £m | £m | £m | |
As at 1 January 2023 | – | 283.6 | 5.4 | 24.6 | 313.6 |
Cash flows: | |||||
– Repayment | – | (25.0) | (5.4) | – | (30.4) |
Non-cash: | |||||
– Interest expense | – | 5.1 | – | – | 5.1 |
– Lease additions | – | – | 1.4 | – | 1.4 |
– Lease liabilities 2 | – | – | 0.1 | (0.4) | (0.3) |
– Reclassification | – | – | 2.8 | (2.8) | – |
As at 31 December 2023 | – | 263.7 | 4.3 | 21.4 | 289.4 |
Cash flows: | |||||
– Repayment | – | – | (5.6) | – | (5.6) |
– Drawdown of RCF (previously held facility) | – | 40.0 | – | – | 40.0 |
– Settlement of loan | – | (305.0) | – | – | (305.0) |
– Drawdown of RCF (new facility) | – | 42.7 | – | – | 42.7 |
– Loan fees paid | – | (2.4) | – | – | (2.4) |
Non-cash: | |||||
– Interest expense | – | 1.4 | – | – | 1.4 |
– Lease additions | – | – | 5.5 | – | 5.5 |
– Lease liabilities 2 | – | – | 0.5 | – | 0.5 |
– Reclassification | – | – | (0.7) | 0.7 | – |
As at 31 December 2024 | – | 40.4 | 4.0 | 22.1 | 66.5 |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Current assets | ||
Cash | 50.5 | 19.8 |
Trade receivables | 74.0 | 54.8 |
Other receivables | 2.7 | 0.8 |
Accrued income | 2.2 | 2.6 |
129.4 | 78.0 | |
Current liabilities | ||
Trade payables | (15.1) | (10.8) |
Amounts due to related parties | (1.0) | – |
Accruals | (22.5) | (19.6) |
(38.6) | (30.4) | |
Non-current liabilities | ||
Long-term accruals | (2.7) | – |
Long-term borrowings | (40.4) | (263.7) |
(43.1) | (263.7) |
31 December 2024 | 31 December 2023 | |
£m | £m | |
Current assets | ||
Short-term derivative assets | – | 0.5 |
– | 0.5 | |
Current liabilities | ||
Short-term derivative liabilities | (1.3) | (0.1) |
(1.3) | (0.1) | |
Non-current liabilities | ||
Long-term derivative liabilities | – | (2.8) |
– | (2.8) |
Less than | One to | Three months | One to | ||
one month | three months | to one year | five years | Total | |
31 December 2024 | £m | £m | £m | £m | £m |
Current assets | |||||
Cash | 50.5 | – | – | – | 50.5 |
Trade receivables | 18.3 | 36.7 | 19.0 | – | 74.0 |
Other receivables | – | 2.7 | – | – | 2.7 |
Accrued income | 2.2 | – | – | – | 2.2 |
Current liabilities | |||||
Short-term derivative liabilities | – | (0.6) | (0.7) | – | (1.3) |
Trade payables | (12.9) | (2.2) | – | – | (15.1) |
Accruals | – | (22.5) | – | – | (22.5) |
Non-current liabilities | |||||
Long-term accruals | – | – | – | (2.7) | (2.7) |
Long-term borrowings | – | – | – | (45.8) | (45.8) |
58.1 | 14.1 | 18.3 | (48.5) | 42.0 |
Less than | One to | Three months | One to | ||
one month | three months | to one year | five years | Total | |
31 December 2023 | £m | £m | £m | £m | £m |
Current assets | |||||
Cash | 19.8 | – | – | – | 19.8 |
Short-term derivative assets | – | 0.3 | 0.2 | – | 0.5 |
Trade receivables | 11.8 | 27.9 | 15.1 | – | 54.8 |
Other receivables | – | 0.8 | – | – | 0.8 |
Accrued income | 2.6 | – | – | – | 2.6 |
Current liabilities | |||||
Short-term derivative liabilities | – | (0.1) | – | – | (0.1) |
Trade payables | (8.8) | (2.0) | – | – | (10.8) |
Accruals | – | (19.6) | – | – | (19.6) |
Non-current liabilities | |||||
Long-term derivative liabilities | – | 0.2 | (0.8) | (2.2) | (2.8) |
Long-term borrowings | – | – | – | (294.1) | (294.1) |
25.4 | 7.5 | 14.5 | (296.3) | (248.9) |
Type of financial | |||
instrument at Level 2 | Measurement technique | Main assumptions | Main inputs used |
Derivative assets and liabilities | Present-value method | Determining the present value of | Observable market exchange |
financial instruments as the current | rates | ||
value of future cash flows, taking | |||
into account current market | |||
exchange rates |
US Dollar | Euro | Other | Total | |
31 December 2024 | £m | £m | £m | £m |
Exposures | ||||
Cash | 27.3 | 1.1 | 16.5 | 44.9 |
Short- and long-term derivative assets/(liabilities) | (0.8) | – | – | (0.8) |
Trade receivables | 41.9 | 7.7 | 3.6 | 53.2 |
Trade accounts payable | (1.3) | – | (0.6) | (1.9) |
Net exposure | 67.1 | 8.8 | 19.5 | 95.4 |
US Dollar | Euro | Other | Total | |
31 December 2023 | £m | £m | £m | £m |
Exposures | ||||
Cash | 7.2 | 1.2 | 6.1 | 14.5 |
Short- and long-term derivative assets/(liabilities) | 0.4 | – | – | 0.4 |
Trade receivables | 30.0 | 4.6 | 2.7 | 37.3 |
Trade accounts payable | (1.0) | – | (0.2) | (1.2) |
Net exposure | 36.6 | 5.8 | 8.6 | 51.0 |
10% decrease | 10% increase | |||
2024 | 2023 | 2024 | 2023 | |
£m | £m | £m | £m | |
Impact on profit before income tax: | ||||
US Dollar | 7.5 | 4.1 | (6.1) | (3.3) |
Euro | 0.9 | 0.6 | (0.8) | (0.5) |
8.4 | 4.7 | (6.9) | (3.8) |
100 basis point decrease | 100 basis point increase | |||
2024 | 2023 | 2024 | 2023 | |
£m | £m | £m | £m | |
Impact on: | ||||
Net earnings before income tax | (0.4) | – | 0.4 | – |
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
Revenue (£m) | 285.5 | 273.1 | 243.2 | 189.3 | 178.4 | 178.2 | 157.6 |
Provision added for bad debt (£m) | 1.0 | 2.3 | 1.1 | 1.4 | 1.7 | 2.9 | 2.4 |
% of revenue | 0.4% | 0.8% | 0.5% | 0.7% | 1.0% | 1.6% | 1.5% |
Trade and other | ||
Trade and other | payables (note 19), | |
receivables | including deferred | |
(note 17) | revenue | |
2024 | £m | £m |
At 31 December 2024 | 89.9 | (160.5) |
At 31 December 2023 | 69.2 | (137.0) |
Consolidated Statement of Financial Position movement | (20.7) | 23.5 |
Transaction costs relating to sale of 40% of Healthcare business to non-controlling interest | (2.8) | 2.8 |
Contingent consideration paid | – | 0.5 |
Tax related adjustments | – | (0.9) |
Movement as a result of business combinations | 9.5 | (21.2) |
Movement as shown in Consolidated Statement of Cash Flows | (14.0) | 4.7 |
Trade and other | ||
Trade and other | payables (note 19), | |
receivables | including deferred | |
(note 17) | revenue | |
2023 | £m | £m |
At 31 December 2023 | 69.2 | (137.0) |
At 31 December 2022 | 62.7 | (137.3) |
Consolidated Statement of Financial Position movement | (6.5) | (0.3) |
Contingent consideration paid | – | 0.2 |
Lease accounting related adjustments | – | (0.6) |
Tax related adjustments | – | (0.4) |
Movement as shown in Consolidated Statement of Cash Flows | (6.5) | (1.1) |
Dilapidations | |||
Right-of-use | Dilapidations | ||
assets | Other | Total | |
£m | £m | £m | |
At 1 January 2023 | 0.5 | 0.9 | 1.4 |
Increase in provision | 0.1 | – | 0.1 |
At 31 December 2023 | 0.6 | 0.9 | 1.5 |
Increase in provision | 0.1 | 0.1 | 0.2 |
At 31 December 2024 | 0.7 | 1.0 | 1.7 |
Current: | 0.2 | – | 0.2 |
Non-current: | 0.5 | 1.0 | 1.5 |
31 December 2024 | 31 December 2023 | |||||
Percentage | Percentage | |||||
of Total | of Total | |||||
No’000s | Shares | £000s | No’000s | Shares | £000s | |
Ordinary shares at 1 January (£0.0001) | 845,028 | 84 | 845,028 | 84 | ||
Cancellation of shares: share buyback programme | (14,133) | (1) | – | – | ||
Ordinary shares at 31 December (£0.0001) | 830,895 | 99.99 | 83 | 845,028 | 99.99 | 84 |
Deferred shares of £1.00 each | 100 | 0.01 | 100 | 100 | 0.01 | 100 |
Total authorised, allotted, called up and fully paid | 830,995 | 100 | 183 | 845,128 | 100.00 | 184 |
Vesting Schedule | 2025 | No. | 2026 | No. | 2027 | No. | Total No. |
Scheme 1* | 603,625 | 603,625 | – | 1,207,250 | |||
Scheme 2** | 6,500,711 | 6,250,000 | 6,250,000 | 19,000,711 | |||
Scheme 4 | 2,600,793 | 5,023,015 | 17,580,554 | 25,204,362 | |||
Total | 9,705,129 | 11,876,640 | 23,830,554 | 45,412,323 | |||
Shares held in trust | (9,705,129) | (11,876,640) | (23,830,554) | (45,412,323) | |||
Net dilution | 0 | 0 | 0 | 0 |
31 December 2024 | |
£m | |
Statement of Financial Position Summary: | |
Non-current assets | 76.1 |
Current assets | 62.7 |
Current liabilities | (59.9) |
Non-current liabilities | (36.1) |
Equity attributable to owners of the Company | 42.8 |
Non-controlling interest | 17.1 |
Year ended | |
31 December 2024 | |
£m | |
Income Statement Summary: | |
Revenue | 63.3 |
Profit after tax | 17.3 |
Other comprehensive income | 2.0 |
Total comprehensive income | 19.3 |
Total comprehensive income – non-controlling interest | 7.7 |
Statement of Cash Flows Summary: | |
Cash flows used in operating activities | (10.5) |
Cash flows used in investing activities | (18.7) |
Cash flows from financing activities | 27.3 |
Total cash flows | (1.9) |
Option | |||
exercise | Remaining | ||
price | life | Number of | |
(pence) (years) | options | ||
31 December 2023 | 1/100th | 0.0 | 4,461,611 |
Exercised | 1/100th | N/A | (3,254,361) |
31 December 2024 | 1/100th | 0.0 | 1,207,250 |
Award tranche | Award 1 | Award 2 | Award 3 | Award 5 | Award 7 | Award 8 | Award 9 |
Grant date | 31/10/19 | 07/05/20 | 25/05/20 | 22/09/20 | 23/03/21 | 31/01/23 | 22/01/24 |
Expected dividend yield | 3.06% | 3.06% | 3.06% | 3.06% | 3.06% | 3.57% | Note 1 |
Volatility | 26.87% | 26.87% | 26.87% | 26.87% | 26.87% | 28.62% | Note 1 |
Initial share price (pre capital | |||||||
reorganisation) | £12.25 | £12.25 | £12.25 | £12.25 | £12.25 | £12.55 | Note 1 |
Initial share price (post capital | |||||||
reorganisation) | £1.72 | £1.72 | £1.72 | £1.72 | £1.72 | £1.76 | Note 1 |
Group achieves £100m EBITDA | |||||||
by 1 March 2024 | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | 100% vest |
Fair value (pre capital | |||||||
reorganisation) | £11.79 | £11.79 | £11.79 | £11.79 | £11.79 | £12.07 | £14.00 |
Fair value (post capital | |||||||
reorganisation) | £1.65 | £1.65 | £1.65 | £1.65 | £1.65 | £1.69 | £1.96 |
Risk-free interest rate | 3.17% | 3.17% | 3.17% | 3.17% | 3.17% | 3.24% | Note 1 |
Estimated forfeiture rate | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Remaining contractual life | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Group achieves £110m EBITDA | |||||||
by 1 March 2025 | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | N/A |
Fair value (pre capital | |||||||
reorganisation) | £11.43 | £11.43 | £11.43 | £11.43 | £11.43 | £11.65 | N/A |
Fair value (post capital | |||||||
reorganisation) | £1.60 | £1.60 | £1.60 | £1.60 | £1.60 | £1.63 | N/A |
Risk-free interest rate | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 3.32% | N/A |
Estimated forfeiture rate | 0% | 0% | 0% | 0% | 0% | 0% | N/A |
Remaining contractual life | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | N/A |
Group achieves £125m EBITDA | |||||||
by 1 March 2026 | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | N/A |
Fair value (pre capital | |||||||
reorganisation) | £11.09 | £11.09 | £11.09 | £11.09 | £11.09 | £11.24 | N/A |
Fair value (post capital | |||||||
reorganisation) | £1.55 | £1.55 | £1.55 | £1.55 | £1.55 | £1.57 | N/A |
Risk-free interest rate | 3.20% | 3.20% | 3.20% | 3.20% | 3.20% | 3.12% | N/A |
Estimated forfeiture rate | 5% | 5% | 5% | 5% | 5% | 4% | N/A |
Remaining contractual life | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | N/A |
Group achieves £145m EBITDA | |||||||
by 1 March 2027 | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | 25% vest | N/A |
Fair value (pre capital | |||||||
reorganisation) | £10.76 | £10.76 | £10.76 | £10.76 | £10.76 | £10.85 | N/A |
Fair value (post capital | |||||||
reorganisation) | £1.51 | £1.51 | £1.51 | £1.51 | £1.51 | £1.52 | N/A |
Risk-free interest rate | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 3.21% | N/A |
Estimated forfeiture rate | 9% | 9% | 9% | 9% | 9% | 4% | N/A |
Remaining contractual life | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | N/A |
Option | |||
exercise | Remaining | ||
price | life | Number of | |
(pence) (years) | options | ||
31 December 2023 | 1/100th | 1.7 | 26,499,998 |
Granted | 1/100th | N/A | 63,529 |
Exercised | 1/100th | N/A | (6,437,816) |
Forfeited | 1/100th | N/A | (1,125,000) |
31 December 2024 | 1/100th | 1.2 | 19,000,711 |
Award tranche | Award 1 | Award 2 | Award 3 | Award 4 | Award 5 |
Grant date | 07/03/22 | 31/01/23 | 23/05/23 | 22/01/2024 | 21/05/2024 |
Expected dividend yield | 3.06% | 3.57% | 3.34% | 1.60% | 1.04% |
Volatility | 26.87% | 28.62% | 29.40% | 28.25% | 29.14% |
Initial share price (pre capital reorganisation) | £12.25 | £12.55 | £13.10 | £13.93 | £16.14 |
Initial share price (post capital reorganisation) | £1.72 | £1.76 | £1.83 | £1.95 | £2.26 |
Group achieves £110m EBITDA by 1 March 2025 | 10% vest | 10% vest | 10% vest | 10% vest | 10% vest |
Fair value (pre capital reorganisation) | £11.43 | £11.65 | £12.35 | £13.68 | £16.01 |
Fair value (post capital reorganisation) | £1.60 | £1.63 | £1.73 | £1.92 | £2.24 |
Risk-free interest rate | 3.24% | 3.32% | 4.10% | 4.72% | 4.74% |
Estimated forfeiture rate | 0% | 0% | 0% | 0% | 0% |
Remaining contractual life | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 |
Group achieves £125m EBITDA by 1 March 2026 | 20% vest | 20% vest | 20% vest | 20% vest | 20% vest |
Fair value (pre capital reorganisation) | £11.09 | £11.24 | £11.94 | £11.94 | £11.94 |
Fair value (post capital reorganisation) | £1.55 | £1.57 | £1.67 | £1.67 | £1.67 |
Risk-free interest rate | 3.20% | 3.12% | 4.02% | 4.17% | 4.27% |
Estimated forfeiture rate | 9% | 8% | 8% | 8% | 0% |
Remaining contractual life | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
Group achieves £145m EBITDA by 1 March 2027 | 70% vest | 70% vest | 70% vest | 70% vest | 70% vest |
Fair value (pre capital reorganisation) | £10.76 | £10.85 | £11.55 | £11.55 | £11.55 |
Fair value (post capital reorganisation) | £1.51 | £1.52 | £1.62 | £1.62 | £1.62 |
Award tranche | Award 1 | Award 2 | Award 3 | Award 4 | Award 5 |
Risk-free interest rate | 3.24% | 3.21% | 3.97% | 3.87% | 4.07% |
Estimated forfeiture rate | 16% | 8% | 8% | 8% | 0% |
Remaining contractual life | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 |
Option | |||
exercise | Remaining | ||
price | life | Number of | |
(pence) (years) | options | ||
31 December 2023 | 1/100th | 2.8 | 19,642,763 |
Granted | 1/100th | N/A | 6,829,456 |
Forfeited | 1/100th | N/A | (1,267,857) |
31 December 2024 | 1/100th | 1.8 | 25,204,362 |
Carrying | Fair value | ||
value | adjustments | Fair value | |
£m | £m | £m | |
Intangible assets consisting of: | |||
Customer relationships | – | 2.0 | 2.0 |
Trade names | – | 1.9 | 1.9 |
Database | – | 0.4 | 0.4 |
Net assets acquired consisting of: | |||
Goodwill | 1.1 | (1.1) | – |
Trade and other receivables | 1.3 | – | 1.3 |
Trade and other payables | (3.6) | 0.6 | (3.0) |
Borrowings | (3.7) | – | (3.7) |
Deferred tax | – | (0.2) | (0.2) |
Fair value of net (liabilities)/assets acquired | (4.9) | 3.6 | (1.3) |
Fair value | |
£m | |
Consideration | 6.3 |
Less working capital adjustment | (0.1) |
Plus net liabilities acquired | 1.3 |
Goodwill | 7.5 |
Carrying | Fair value | ||
value | adjustments | Fair value | |
£m | £m | £m | |
Intangible assets consisting of: | |||
Customer relationships | – | 9.6 | 9.6 |
Database | – | 3.2 | 3.2 |
Trade names | – | 0.7 | 0.7 |
Net assets acquired consisting of: | |||
Property, plant and equipment | 1.5 | – | 1.5 |
Intangible assets | 0.7 | – | 0.7 |
Cash and cash equivalents | 1.6 | – | 1.6 |
Trade and other receivables | 0.8 | – | 0.8 |
Trade and other payables | (6.5) | 0.4 | (6.1) |
Short and long-term lease liabilities | (1.0) | – | (1.0) |
Deferred tax | – | (0.7) | (0.7) |
Fair value of net (liabilities)/assets acquired | (2.9) | 13.2 | 10.3 |
Fair value | |
£m | |
Consideration | 18.4 |
Contingent consideration, not conditional on employment | 3.1 |
Less net assets acquired | (10.3) |
Goodwill | 11.2 |
Carrying | Fair value | ||
value | adjustments | Fair value | |
£m | £m | £m | |
Intangible assets consisting of: | |||
Customer relationships | – | 4.6 | 4.6 |
Database | – | 5.4 | 5.4 |
Trade names | – | 1.1 | 1.1 |
Net assets acquired consisting of: | |||
Trade and other receivables | 3.6 | – | 3.6 |
Trade and other payables | (5.4) | 0.2 | (5.2) |
Deferred tax | – | (0.4) | (0.4) |
Fair value of net (liabilities)/assets acquired | (1.8) | 10.9 | 9.1 |
Fair value | |
£m | |
Consideration | 19.2 |
Less net assets acquired | (9.1) |
Goodwill | 10.1 |
Carrying | Fair value | ||
value | adjustments | Fair value | |
£m | £m | £m | |
Intangible assets consisting of: | |||
Customer relationships | – | 10.1 | 10.1 |
Trade names | – | 5.6 | 5.6 |
Net assets acquired consisting of: | |||
Property, plant and equipment | 0.4 | – | 0.4 |
Cash and cash equivalents | 7.3 | – | 7.3 |
Trade and other receivables | 3.9 | – | 3.9 |
Corporation tax | 0.2 | – | 0.2 |
Trade and other payables | (11.9) | – | (11.9) |
Short and long-term lease liabilities | (0.4) | – | (0.4) |
Borrowings | (7.0) | – | (7.0) |
Deferred tax | 0.2 | (4.0) | (3.8) |
Fair value of net (liabilities)/assets acquired | (7.3) | 11.7 | 4.4 |
Fair value | |
£m | |
Consideration paid in cash | 20.8 |
Consideration settled via issuance of related party loan note | 1.0 |
Less net assets acquired | (4.4) |
Goodwill | 17.4 |
31 December 2024 | |
£m | |
Presented within Operating Activities | |
Acquisition of TS Lombard: | |
Contingent consideration | 0.5 |
0.5 |
31 December 2024 | |
£m | |
Presented within Investing Activities | |
Acquisition of BTMI: | |
Cash consideration | 6.3 |
Working capital adjustment | (0.1) |
Acquisition of Jobdig, Inc: | |
Cash consideration | 18.4 |
Cash acquired | (1.6) |
Settlement of transaction costs (not included within consideration) | 3.8 |
Acquisition of Celent: | |
Cash consideration | 19.2 |
Acquisition of Deallus: | |
Cash consideration | 20.8 |
Cash acquired | (7.3) |
Settlement of transaction costs (not included within consideration) | 5.2 |
SIA – Strategy in Action Limited | |
Cash consideration | 4.0 |
68.7 |
31 December 2024 | |
£m | |
Presented within Financing Activities | |
Acquisition of BTMI: Settlement of borrowings (not included within consideration) | 3.7 |
Acquisition of Deallus: Settlement of borrowings (not included within consideration) | 7.0 |
10.7 |
Subsidiary undertaking | Principal activity | Country of registration | Registered address | |
GlobalData Australia Pty Limited | Data and analytics | c/o Brown Hamilton Partners, Unit 1, | ||
Australia | 31-39 Norcal Road, Nunawading, | |||
GD Healthcare Australia Pty Limited** | Data and analytics | Victoria 3131, Australia | ||
GlobalData Brasil, serviços e | Data and analytics | Brazil | Rua Tuiuti, 436 Conj 31 – Tatuapé, | |
informações empresariais Ltda.* | São Paulo – SP, 03081-003, Brazil | |||
Adfinitum Networks Inc* | Data and analytics | 77 King Street West, Suite 400, Toronto, | ||
GD Healthcare Canada Inc** (formerly | Data and analytics | Canada | Ontario, M5K 0A1, Canada | |
GlobalData Canada Inc) | ||||
Deallus Consulting China Limited** | Data and analytics | China | Room 1201, | Block 1, No. 258 Zhijiang |
Road, Fengxian District, Shanghai, China | ||||
GlobalData Trading (Shanghai) Co | Data and analytics | China | Room 368, Area 302, No.211, North Fute | Road, Pilot Free Trade Zone, Shanghai, |
Limited** | China | |||
GlobalData Information Services | Suite 1016J, 10th Floor, Building 1, | |||
(Shanghai) Co. Ltd* (formerly LMC | Data and analytics | China | No. 1728-1746 West Nanjing Road, | |
Automotive Consulting (Shanghai) | Jing’an District, Shanghai, China | |||
Co. Ltd) | Unit 35, 13/f Gem Tower, 1306A, | |||
Langbo Economic Research and | Data and analytics | China | Xizhilang Building, No.2022, Community | |
Consulting (Shenzhen) Co Ltd* | Center Road, Yuehai St, Nanshan District, | |||
Shenzhen, China | ||||
Lombard Street Research (Asia) | Data and analytics | Unit 4, 16/F, Bonham Trade Centre, | ||
Limited* | China | 50 Bonham Strand, Sheung Wan, | ||
TS Lombard (Asia) Limited* | Non-trading | Hong Kong |
Subsidiary undertaking | Principal activity | Country of registration | Registered address |
ALF Insight Limited* (1) | Data and analytics | ||
Business Trade Media International | Data and analytics | ||
Limited* (1) | |||
Canadean Limited (1) | Data and analytics | ||
GD UK Healthcare Limited** (1) | Data and analytics | ||
GD Healthcare Holding Limited** (1) | Holding company | ||
GlobalData Holding Limited (1) | Holding company | ||
GlobalData Investments Limited* (1) | Non-trading | ||
GlobalData UK Limited* | Data and analytics | ||
GlobalData EBT Trustees Limited* (1) | Non-trading | ||
Internet Business Group Limited (1) | Performance | ||
advertising | |||
LMC Automotive Limited* (1) | Data and analytics | ||
LMC International Limited* (1) | Data and analytics | ||
Lombard Street Research Limited* (1) | Data and analytics | John Carpenter House, | |
Lombard Street Research Financial | Data and analytics | England & Wales | John Carpenter Street, |
Services Limited* | London, EC4Y 0AN, | ||
United Kingdom | |||
Media Business Insight Limited* (1) | Data and analytics | ||
Media Business Insight Holdings | Holding company | ||
Limited* (1) | |||
Progressive Content Limited* (1) | Data and analytics | ||
Progressive Digital Media (Holdings) | Holding company | ||
Limited (1) | |||
Progressive Digital Media Limited (1) | Data and analytics | ||
Research Views Limited* (1) | Holding company | ||
Trusted Sources Limited* (1) | Non-trading | ||
Trusted Sources UK Limited* (1) | Data and analytics | ||
TSL Research Group Limited* (1) | Holding company | ||
Washington Topco Limited | Holding company | ||
Washington Midco Limited** (1) | Holding company | ||
Washington Bidco Limited** (1) | Holding company | ||
Deallus Consulting Limited** | Data and analytics | ||
Deallus Holdings Limited** | Data and analytics | 1 Poultry, | |
Galahad Bidco Limited** | Holding company | England & Wales | London, ED2R 8EJ, |
Galahad Midco Limited** | Holding company | United Kingdom | |
Galahad Topco Limited** | Holding company | ||
GlobalData France SAS* | Data and analytics | France | 133 bis Rue de l’Universite, 75007, |
Paris, France | |||
Deallus Consulting India Private | Unit No. 705-708, 7th Floor, JMD Regent | ||
Limited** | Data and analytics | India | Square. MG Road, Gurugram, DLF QE, |
Gurgaon, Haryana, 122002, India |
Subsidiary undertaking | Principal activity | Country of registration | Registered address | |
GD Research Centre Private Limited* | Data and analytics | 3rd Floor, Jyothi Pinnacle Building, SY | ||
Vatrix Healthcare Data India Private | Data and analytics | India | No.11, Kondapur Village, Serilingampally | |
Limited** | Mandal, Ranga Reddy Dist, Hyderabad, | |||
Telangana- 500081, India | ||||
15F Toranomon Hills Business Tower, | ||||
Deallus Consulting Japan K.K** | Data and analytics | Japan | 1-17-1 Toranomon, Minato-ku, Tokyo, | |
105 6415, | Japan | |||
GD Healthcare Japan KK** (formerly | Data and analytics | |||
GlobalData Japan KK) | Japan | Tokyo Club Building 11F, 3-2-6 | ||
Kasumigaseki, Chiyoda-ku, Tokyo, Japan | ||||
GlobalData Japan KK* | Data and analytics | |||
Canadean Mexico Y Centro America, | Avenida Ejército Nacional 769 Piso 2. | |||
F. De R.L. De C.V* | Data and analytics | Mexico | Colonia Granada. Alcaldía Miguel Hidalgo. | |
CP 11520. | Ciudad de México | |||
GlobalData Poland sp. z o.o* | Data and analytics | Poland | ul. Grzybowska 2/29, 00-131, Warsaw, | |
Poland | ||||
Deallus Consulting (Singapore) | Data and analytics | Singapore | 3791 | Jalan Bukit Merah, 03-03 E-Centre, |
PTE Ltd** | Redhill, Singapore 159471 | |||
The Executive Centre Singapore, Capital | ||||
GlobalData Pte Limited* | Data and analytics | Singapore | Square, Level 7 Capital Square, | |
23 Church Street, Singapore 049481 | ||||
Samsung-dong, ASEM tower, 37th Floor, | ||||
Progressive Media Korea Limited* | Data and analytics | South Korea | 517 | Yeongdong-daero, Gangnam Gu, |
Seoul, Republic of Korea | ||||
Dogok-dong, Tower Palace, Rm. 2005, | ||||
GD Healthcare Korea Limited** | Data and analytics | South Korea | 20th Floor, Je Di-dong, | |
56 Eonju-ro 30-gil, Gangnam-gu, Seoul, | ||||
Republic of Korea | ||||
Deallus AB** | Data and analytics | Sweden | Massingsgatan 5 42671, Vastra, Frolun, | |
Sweden | ||||
GlobalData Switzerland GmbH* | Data and analytics | Switzerland | Route de Divonne 44, 1260 Nyon, | |
Switzerland | ||||
66 Q. House Asoke Building, Room | ||||
LMC Automotive (Thailand) Company | Data and analytics | Thailand | no.1106, | 11th floor, Sukhumvit 21 Road, |
Limited* | Klongtoeynua, Watthana, Bangkok 10110, | |||
Thailand | ||||
MEED Media FZ LLC* | Data and analytics | United Arab Emirates | GBS Building, 6th Floor, Dubai Media City, | |
Dubai, United Arab Emirates | ||||
11500 | West Olympic Boulevard, | |||
Deallus Consulting Inc** | Data and analytics | United States of America | Los Angeles, CA 90064, | |
United States of America | ||||
GlobalData US, Inc | Data and analytics | 441 | Lexington Avenue, 2nd Floor, | |
Global Data Publications, Inc** | Data and analytics | United States of America | New York, NY, 10017, | |
United States of America |
17%England & WalesData and analytics | ||||
Subsidiary undertaking | Principal activity | Country of registration | Registered address | |
430 | First Avenue North, Suite 790, | |||
JobDig, Inc* | Data and analytics | United States of America | Minneapolis, MN 55401, | |
United States of America | ||||
LMC Automotive US, Inc* | Data and analytics | United States of America | 2285 | South Michigan Road, Eaton Rapids, |
Michigan 48827, United States of America | ||||
Lombard Street Research (US), Inc* | Data and analytics | United States of America | 15 E. North St. Dover, Delaware 19901, | |
United States of America | ||||
6671, | Sunset Blvd, Suite 1525, | |||
Media Business Insight, Inc* | Data and analytics | United States of America | Los Angeles, CA 90028, | |
United States of America |